Shandong Xinhua pharmaceutical co., ltd

Xinhua Pharmaceutical, formerly known as Shandong Xinhua Pharmaceutical Factory, was established in Jiaodong Anti-Japanese Base Area 1943. The company covers an area of nearly 3 million square meters and employs more than 5,000 people. It is a key large pharmaceutical enterprise in China, the largest production and export base of antipyretic and analgesic drugs in Asia, and an important domestic manufacturer of cardiovascular and cerebrovascular drugs, anti-infective drugs and central nervous system drugs. It has a high enterprise status and influence in the chemical and pharmaceutical industries in China. The company is a H-share and A-share listed company, one of the top ten scientific and technological innovation enterprises in China pharmaceutical industry and one of the top 50 pharmaceutical companies in China. At present, it has 9 holding subsidiaries. "Xinhua Brand" trademark is a well-known trademark in China, and it is an export brand cultivated and developed by the Ministry of Commerce.

At present, the company has an annual output of more than 25,000 tons of chemical raw materials. It is the world's largest manufacturer of analgin, ibuprofen, aspirin, caffeine, levodopa and other drugs. There are 654.38+00 raw material special varieties such as ethiprole, and the market share of 8 raw material leading varieties ranks first in China. The annual production capacity of the preparation is 8 billion tablets, 300 million injections and 200 million capsules. Since its establishment, the company has always adhered to the principle of putting science and technology first and quality first, and pursued the quality concept of "product quality is related to enterprise life and drug quality is related to people's life", and strictly controlled quality in production and kept improving. The company is the first pharmaceutical and chemical enterprise in China that has passed ISO900 1, ISO 1400 1 and ISO100/2 certification. All the API products and preparation forms in production have passed GMP certification, 8 products such as theophylline and ibuprofen have passed FDA certification, and theophylline and aspirin are 65438+. Meanwhile, many products have been registered in Russia, India and other countries. The main technical and economic indicators of most leading varieties are in the leading position in China, which is higher than the certification standards at home and abroad.

The company has established a relatively complete scientific research and development system, is a national high-tech enterprise and a key high-tech enterprise of the National Torch Program, has the first batch of national enterprise technology centers and postdoctoral workstations, has created the Industry-University-Research model in the same industry in China, has carried out in-depth cooperation with more than 50 scientific research institutions, and has achieved some scientific research results. At present, there are 7 national first-class new drug numbers and 6 authorized patents 106.

After more than 60 years of development, the company has built four production parks, namely, General Factory Park, Dongyuan Park, Xiyuan Park and Xinhua International Pharmaceutical Industrial Park, forming a reasonable layout of chemical raw materials, pharmaceutical preparations, pharmaceutical and chemical intermediates and pharmaceutical commerce. In the future, the company will persist in taking Scientific Outlook on Development as the leader, relying on four parks and four sectors, taking independent innovation as the driving force, taking structural optimization and upgrading as the starting point, taking product leadership as the leader, and taking industrial chain acquisition and expansion as the development strategy. Give priority to medicine, tilt the main business and do a good job in auxiliary business-feed back the development of the main business of medicine with real estate, do a good job in raw materials and pharmaceutical and chemical intermediates, and highlight the development idea of strengthening preparations. Unswervingly follow the road of scientific development, harmonious development and international development, practice internal strength, expand the market, adjust the structure, increase efficiency, achieve sound and rapid development, and make new and greater contributions to the development of China's pharmaceutical industry!

The company's environmental policy:

Our company is a large-scale enterprise with chemical synthetic raw materials and pharmaceutical preparations as its leading products, with the mission of "protecting health and benefiting society", following the core values of "quality first and scientific development" and adhering to the road of sustainable development in harmony with the environment.

Environmental protection is the lifeline of Xinhuanet's survival and development.

To this end, we promise:

Abide by applicable laws, regulations and other relevant requirements of the company, continuously improve the awareness and quality of all employees, and enhance the ability to fulfill environmental obligations.

We will continue to apply the environmental strategy of prevention from the source to the design, manufacture and service of products, constantly adjust the product structure, improve technology and equipment, reduce the consumption of raw materials, promote the recycling of resources and energy, and reduce pollutant emissions.

Formulate feasible environmental objectives and indicators and review them regularly, and continuously improve the environmental management system and environmental performance. Actively cooperate with relevant parties and consciously accept public supervision.